Nuvasive, Inc. (NUVA) Sees FY14 Revenue of $761M, FY15 Revenue of $810M

• Preliminary full-year 2014 revenue of approximately $761 million; reflects 11% growth over the prior year, or 12% on a constant currency basis
• Preliminary full-year 2014 non-GAAP operating margin anticipated to exceed guidance of 16.5%
• Full-year 2015 revenue of approximately $810 million, including the impact of currency headwinds
• Estimating 2015 non-GAAP operating margin expansion of approximately 250 basis points versus full-year 2014

NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive procedural solutions for spine surgery, today provided a business and financial performance update, including the announcement of select preliminary unaudited financial results for the full-year ended December 31, 2014 and the issuance of select performance guidance for the full-year 2015.

Alex Lukianov, Chairman and Chief Executive Officer, said, "2014 was another strong year for NuVasive as we continue to drive toward $1 billion in revenues and beyond. Revenue growth was approximately 12% on a constant currency basis, outperforming our expectations and well ahead of the spine market's overall growth. We continue to successfully execute our market share-taking strategy, including penetrating the traditional market through less invasive solutions such as Precept® and MAS PLIF® as well as expanding internationally, both of which are contributing significantly to our growth. At the same time, we are also delivering increased profitability as we drive meaningful operating margin expansion through insourcing manufacturing, improving asset efficiencies and scaling our international business."

Lukianov continued, "As we enter 2015, we remain focused on the consistent execution of our strategy to drive growth and profitability as we look to extend our leadership position further with game-changing minimally disruptive procedural solutions for the spine. Our ongoing commitment to share-taking in MIS, traditional and international markets -- coupled with ever-increasing operating leverage -- places us in an excellent position to continue to deliver increasing value to our shareholders."

Full-Year 2014 Preliminary Results

NuVasive anticipates full-year 2014 revenue will approximate $761 million. Previously issued guidance for this metric was approximately $755 million. NuVasive also anticipates preliminary fourth quarter 2014 revenue performance of approximately $203 million. The Company also anticipates that full-year 2014 non-GAAP operating margin will exceed previously issued guidance of approximately 16.5%, with guidance alone reflecting more than 150 basis points of expansion in operating margin versus the full-year 2013. Driving this anticipated full-year 2014 non-GAAP operating margin performance is NuVasive's preliminary anticipation of fourth quarter 2014 non-GAAP operating margin of approximately 20%.

Full-Year 2015 Outlook

NuVasive expects full-year 2015 revenue to grow approximately 6% year-over-year to $810 million, which includes approximately $8 million in currency headwinds. On a constant currency basis, the Company expects revenue growth of approximately 7.5%, in line with the mid to high single-digit revenue growth expectations that the Company communicated previously. Revenue guidance for the full-year 2015 contemplates continued market share gains within a stabilizing domestic spine market. NuVasive is also targeting full-year 2015 non-GAAP operating margin expansion of approximately 250 basis points compared to full-year 2014, which includes approximately 100 basis points of core improvement plus approximately 150 basis points of improvement due to the expiration of a majority of Medtronic related patent royalty obligations.

(Street sees FY14 revenue of $758.16 FY15 revenue of $811.71 million)

Complete Fourth Quarter and Full-Year 2014 Results

The Company will announce complete financial and operating results of its fourth quarter and the full-year ended December 31, 2014, and will provide detailed revenue and profitability guidance for the full-year 2015 after the market closes on February 24, 2015. The Company will hold a conference call that day at 5:30 p.m. ET (2:30 p.m. PT). The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available online from the Investor Relations page of the Company's corporate website at www.nuvasive.com.

After the live webcast, the call will remain available on NuVasive's website, www.nuvasive.com, through March 24, 2015. In addition, a telephone replay of the call will be available until March 10, 2015. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use pin number: 13598479.

You May Also Be Interested In

• Tractor Supply (TSCO) Tops Q1 EPS by 12c ; Offers Guidance
• Grainger (GWW) Tops Q1 EPS by 2c, provides guidance
• Union Pacific (UNP) Tops Q1 EPS by 18c